NCT01205867View on ClinicalTrials.gov

Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

January 31, 2012

Conditions

Butyrylcholinesterase Deficiency

Interventions

DRUG

AZD8848

Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg

Trial Locations (1)

Unknown

Research Site, Copenhagen

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY